Here, we describe the implementation and interpretation of the results of an in vitro mammosphere self-renewal quantitative assay.
The mammary gland is characterized by extensive regeneration capacity, as it goes through massive hormonal changes throughout the life cycle of a female. The role of mammary stem cells (MaSCs) is widely studied both in the physiological/developmental context and with regards to breast carcinogenesis. In this aspect, ex vivo studies focused on MaSC properties are highly sought after. Mammosphere cultures represent a surrogate of organ formation and have become a valuable tool for both basic and translational research. Here, we present a detailed protocol for the generation of murine primary mammosphere cultures and the quantitation of MaSC growth properties. The protocol includes mammary gland collection and digestion, isolation of primary mammary epithelial cells (MECs), establishment of primary mammosphere cultures, serial passaging, quantitation of mammosphere growth parameters and interpretation of the results. As an example, we present the effect of low-level constitutive Myc expression on normal MECs leading to increased self-renewal and proliferation.
Isolation and in vitro culture of mammary epithelial stem and progenitor cells have become essential for understanding their properties in mammary cell biology. Elegant lineage tracing and serial transplantation assays have enabled the study of stem cells (SCs) and other tissue subsets in the context of their in vivo niche. However, this approach is time consuming and requires the generation of reporter mouse models1,2,3,4,5. Therefore, in vitro culture and propagation of mammary stem cells (MaSCs) while sparing key stemness features, namely self-renewal and differentiation ability, is one of the biggest challenges in the field. In the last years, the mammosphere assay has been widely used to model both normal mammary tissue and breast cancer growth, to quantify normal or cancer SCs (CSCs) and assess their self-renewal ability as a surrogate reporter of their activity in their respective in vivo context6,7,8,9,10,11.
The mammosphere assay is an efficient and cost-effective approach, in which freshly isolated mammary epithelial cells (MECs) are cultured in non-adherent conditions, with the premise that only MaSCs will survive and form spheres in suspension while all the other cell types will die by anoikis. Moreover, the ability to form several generations of mammospheres in serial non-adherent passages is related to the self-renewal ability of the MaSCs6,9,11. Here, we describe a detailed protocol of a quantitative mammosphere assay, which was initially developed by Dontu and colleagues7 as a modification of the pioneering neurosphere assay12, enabling the growth of putative SCs in non-adherent, serum-free conditions with the addition of appropriate growth factors7,12.
In vivo procedures were performed in accordance with EU directive 2010/63 and after approval from our institutional ethics committee (Organism for Animal Wellbeing–OPBA) and the Italian Ministry of Health (IACUC Numbers 762/2015 and 537/2017).
1. Murine Mammary Gland Collection and Digestion
2. Isolation of Primary Murine MECs
3. Serial Mammosphere Re-plating
4. Sphere Enumeration Using Digital Image Analysis (DIA)
5. Cumulative Growth Curve Calculation
NOTE: The number of mammospheres counted in each well at the end of each passage (PN) reflects the number of mammosphere-initiating cells seeded at the beginning of PN.
Myc overexpression in normal MECs, leads to an increased frequency of mammosphere initiating cells. This is achieved through a double mechanism: Myc increases the rate of MaSC symmetric divisions and the frequency of progenitor reprogramming into new MaSCs11. To test the effect of low constitutive Myc expression, we used the Rosa26-MycER transgenic mouse model, in which Myc activity can be induced by 4-hydroxytamoxifen (4-OHT)15. We first plated the MECs on ultra-low adhesion 6-well plates to remove fibroblasts, in the absence of 4-OHT. After the first passage, we split the culture in two: two wells were kept untreated (control) and two wells were treated with 200 nM 4-OHT (MycER). We counted the sphere and cell numbers of 5 consecutive passages for three independent experiments (Table 1). The cumulative cell and sphere numbers per passage are shown on Table 2. Induction with 4-OHT leads to increased sphere and cell growth rates, as shown in Figure 1.
Figure 1: Representative results. Cumulative sphere (A) and cell (B) growth curves of control and MycER mammospheres. Mean and standard deviation of 3 independent experiments are shown. Please click here to view a larger version of this figure.
1st plating | 2nd plating | 3rd plating | 4th plating | 5th plating | ||||||||||||
Cells Plated | Cell Count | Sphere Count | Cells Plated | Cell Count | Sphere Count | Cells Plated | Cell Count | Sphere Count | Cells Plated | Cell Count | Sphere Count | Cells Plated | Cell Count | Sphere Count | ||
Exp1 | Control | 77,000 | 50,000 | 31 | 65,000 | 58,500 | 41 | 57,000 | 30,000 | 32 | 30,000 | 22,000 | 5 | 22,000 | 0 | 0 |
77,000 | 81,000 | 41 | 65,000 | 55,000 | 23 | |||||||||||
MycER | 77,000 | 31,0000 | 193 | 80,000 | 375,000 | 323 | 80,000 | 380,000 | 217 | 80,000 | 220,000 | 223 | 80,000 | 170,000 | 155 | |
77,000 | 110,000 | 142 | 80,000 | 505,000 | 396 | 80,000 | 270,000 | 149 | 80,000 | 290,000 | 194 | 80,000 | 250,000 | 160 | ||
Exp2 | Control | 75,000 | 75,000 | 71 | 60,000 | 17,000 | 34 | 28,000 | 45,000 | 29 | 45,000 | 13,000 | 2 | 13,000 | 0 | 0 |
75,000 | 47,000 | 45 | 60,000 | 11,000 | 47 | |||||||||||
MycER | 75,000 | 200,000 | 188 | 80,000 | 225,000 | 277 | 80,000 | 230,000 | 155 | 80,000 | 210,000 | 211 | 80,000 | 100,000 | 95 | |
75,000 | 250,000 | 192 | 80,000 | 202,500 | 283 | 80,000 | 305,000 | 185 | 80,000 | 160,000 | 237 | 80,000 | 100,000 | 133 | ||
Exp3 | Control | 82,500 | 130,000 | 121 | 80,000 | 45,000 | 105 | 80,000 | 110,000 | 86 | 80,000 | 58,500 | 75 | 58,500 | 58,500 | 78 |
82,500 | 125,000 | 177 | 80,000 | 71,250 | 42 | |||||||||||
MycER | 82,500 | 325,000 | 457 | 80,000 | 610,000 | 327 | 80,000 | 367,000 | 309 | 80,000 | 500,000 | 260 | 80,000 | 115,000 | 146 | |
82,500 | 475,000 | 463 | 80,000 | 455,000 | 392 | 80,000 | 415,000 | 204 | 80,000 | 470,000 | 295 | 80,000 | 185,000 | 161 |
Table 1: Numbers of spheres counted and numbers of cells plated and counted at each passage.
Table 2: Calculation of plated sphere numbers and cumulative sphere and cell numbers. Please click here to view a larger version of this table. (Right-click to download.)
Here, we describe a protocol for the quantitative description of MaSC growth properties in vitro. As an example, we present the effect of low-level constitutive Myc expression on normal murine MaSCs. This approach, however, can be equally applied to various contexts. Human or murine primary cells, as well as established cell lines, can be cultured in anchorage independent conditions to establish mammosphere cultures that can be serially passaged. Gene overexpression and RNA interference can be easily introduced in the protocol with the addition of a viral transduction step at the end of the first passage (after step 3.5). Alternatively, cells can be infected in adhesion and then plated as mammospheres.
A critical aspect of the assay presented here is the seeding cell density, which should be low enough to avoid the generation of aggregates interfering with the interpretation of the results16,17. The morphology of the mammospheres can be informative to resolve this ambiguity. Only compact, round spheres should be enumerated at the end of each passage. Both the circularity of the spheroids and the size should be taken into consideration. Using the automated process of the DIA, this step is ensured with the appropriate thresholds in an objective and absolute manner. Often, progenitors will form acinar structures or smaller clusters of cells which should be excluded from the mammosphere counts. As a rule of thumb, we use a threshold of 100 µm diameter. Finally, care should be taken to avoid the transfer of intact or non-fully dissociated mammopsheres from one passage to the next. On the other hand, excess pipetting will lead to increased cell death. Thus, if such difficulties are encountered, we recommend using mild trypsinization or Accutase treatment and passing the dissociated spheres through a 40 µm strainer to ensure the generation of single-cell suspensions.
Sphere forming efficiency (SFE) has been used alternatively, as a surrogate for SC or CSC quantitation ex vivo in mammosphere cultures. SFE is indeed a measure of stem-like cells in a given cell population. However, it represents a less conscientious approach since it provides information only at distinct time points. The calculation of cumulative sphere numbers and the generation of cumulative growth curves, instead, enables the inference of the growth rate of the culture from the initial cell seeding step until the culture exhausts or, in the case of immortalized cultures, for the desired number of passages. The assessment of growth properties allows the evaluation of the deviation from the exponential growth through the coefficient R2 and, at a second step, the assessment of the GR value itself.
Importantly, cumulative mammosphere growth curves can be used to evaluate the effect of small molecule inhibitors or other chemotherapeutic drugs selectively at the CSC level6,11. Contrary to normal primary mammospheres, which functionally exhaust in 5-7 passages, tumor mammospheres tend to expand indefinitely. This feature is linked to the unlimited CSC self-renewal ability. The effects on proliferation and CSC self-renewal can be uncoupled through the generation of tumor cell and mammosphere growth curves, respectively. A CSC-specific effect is expected to result in a decrease in the cumulative mammosphere growth rate, with or without effect on the cumulative cell growth rate6,11.
Finally, another area of interest is the one of adult tissue SC reprogramming. Fully grown mammospheres consist of a phenotypically heterogeneous cell population, in which only a minor fraction retains stem-like features, including mammosphere-initiating ability and mammary gland regeneration upon transplantation in vivo6,9,11,18,19. Mammary progenitors can be thus isolated either using in vitro label-retaining assays6,9,11 or, ex vivo, using established surface markers2,3. Notably, mammary progenitors do not survive anoikis and are unable to form mammospheres. Enforced Myc expression has been shown to confer mammosphere initiation potential to mammary progenitors isolated as PKHneg11, resulting in the generation of a culture that can be passaged indefinitely. Similarly, interference of negative regulators of physiological reprogramming can be tested using the same assay. In this context, a common issue that may arise is the limited number of cell input. If the cell input is lower than 10,000 cells, we recommend seeding in 24-well plates (maximum 5,000 viable cells/mL). Nevertheless, anchorage independent culture conditions can be proven to be too harsh for scoring reprogramming, especially in cases where the reprogramming effect is not immediate. In such cases, the use of a supportive matrix and 3-dimensional organoid cultures could be more appropriate20.
Overall, the mammosphere assay is a cost-effective option that can be easily employed for scoring stem-like properties in normal and tumoral MEC populations. The quantitative approach taken in this protocol facilitates the comparisons between cultures carried out in different conditions or exposed to diverse stimuli. When followed rigorously, it provides a relatively simple ex vivo model system that permits uncoupling of the multiple players that define stem properties in vivo, offering the possibility of more detailed mechanistic studies.
The authors have nothing to disclose.
We thank Bruno Amati for the kind gift of the Rosa26-MycER transgenic mouse model. This work was funded by grants from WWCR, AIRC, ERC, and the Italian Ministry of Health to P.G.P. T.V. and X.A. were supported by FIRC and A.S. by a FUV grant.
ACK lysis buffer | Lonza | 10-548E | Ammonium-chloride-potassium lysis bufer, 100 mL. |
B27 | Invitrogen | 17504-044 | B27 supplement 50X (10 mL). Final concentration 2% v/v. |
bFGF | Peprotech | 100-18B | Human recombinant fibroblast growth factor – basic, 50 μg. Stock solution 100 μg/μL in Tris 5 mM pH 7.6. Final dilution 0.02% v/v. |
Collagenase | Sigma | C2674 | Collagenase from Clostridium histolyticum. Type I-A, lyophilized powder, 1 g. Stock 20,000 U/mL in DMEM. Final dilution 1% v/v. |
DMEM | Lonza | 12-614F | Dulbecco's modified Eagle's medium |
DPBS | Microgem | S17859L0615 | Dulbecco's phosphate buffered saline |
EGF | Tebu-Bio | AF-100-15 | Recombinant human epithelial growth factor. Stock solution 100 μg/mL in sterile dH2O. Final dilution 0.02% v/v. |
Glutamine | Lonza | 17-605E | L-Glutamine, 200 mM. Final dilution 1% v/v. |
Heparin | PharmaTex | 34692032 | Stock concentration 5,000 IU/mL. Final dilution 0.008% v/v. |
Hyaluronidase | Sigma | H4272 | Type IV-S, powder, 750-3,000 U/mg solid, 30 mg. Stock solution 10 mg/mL in sterile dH2O. Final dilution 1% v/v. |
Hydrocortisone | Sigma | H0888 | Stock concentration 100 μg/mL. Final dilution 0.5% v/v. |
Insulin | SAFCBiosciences | 91077C | Insulin, human recombinant, dry powder, 250 mg. Stock concentration 1 mg/mL. Final dilution 0.5% v/v. |
Low attachment 6-well plates | Corning | 351146 | Sterile 6-well not treated cell culture plates with clear flat bottom and lid. |
MEBM | Lonza | CC-3151 | Mammary epithelial cell growth basal medium |
Penicllin-Streptomycin mixture | Lonza | 17-602F | Contains 10,000 U potassium penicillin and 10,000 µg streptomycin sulfate per mL in 0.85% saline. Final dilution 1% v/v. |
Poly-HEMA | Sigma | P3932 | Dissolve in 95% EtOH overnight at 55 °C. Stock concentration 12% w/v. Final dilution 1% v/v in 95% EtOH. Filter (0.22 μm) before use. |